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Abstract
Background: Because HIV viral suppression is essential for optimal outcomes and prevention 
efforts, understanding trends and predictors is imperative to inform public health policy.
Objective: To evaluate viral suppression trends in people living with HIV (PLWH), including the 
relationship of associated factors, such as demographic characteristics and integrase strand transfer 
inhibitor (ISTI) use.
Design: Longitudinal observational cohort study.
Setting: 8 HIV clinics across the United States.
Participants: PLWH receiving clinical care.
Measurements: To understand trends in viral suppression (≤400 copies/mL), annual viral 
suppression rates from 1997 to 2015 were determined. Analyses were repeated with tests limited 
to 1 random test per person per year and using inverse probability of censoring weights to address 
loss to follow-up. Joint longitudinal and survival models and linear mixed models of PLWH 
receiving antiretroviral therapy (ART) were used to examine associations between viral 
suppression or continuous viral load (VL) levels and demographic factors, substance use, 
adherence, and ISTI use.
Results: Viral suppression increased from 32% in 1997 to 86% in 2015 on the basis of all tests 
among 31 930 PLWH. In adjusted analyses, being older (odds ratio [OR], 0.76 per decade [95% 
CI, 0.74 to 0.78]) and using an ISTI-based regimen (OR, 0.54 [CI, 0.51 to 0.57]) were associated 
with lower odds of having a detectable VL, and black race was associated with higher odds (OR, 
1.68 [CI, 1.57 to 1.80]) (P < 0.001 for each). Similar patterns were seen with continuous VL 
levels; when analyses were limited to 2010 to 2015; and with adjustment for adherence, substance 
use, or depression.
Limitation: Results are limited to PLWH receiving clinical care.
Conclusion: HIV viral suppression rates have improved dramatically across the United States, 
which is likely partially attributable to improved ART, including ISTI-based regimens. However, 
disparities among younger and black PLWH merit attention.
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Approximately 1.2 million adults are living with HIV in the United States, with a 
disproportionate burden among men who have sex with men and among African Americans 
(1). Since 1996, the availability of potent antiretroviral therapy (ART) has led to large 
decreases in HIV-related mortality and morbidity. Antiretroviral therapy has transformed 
HIV from a fatal disease into a manageable chronic illness for people living with HIV 
(PLWH) who are aware of their infection and can access and adhere to ART. Furthermore, 
ART regimens have become increasingly better tolerated and easier to take (2).
Achieving and maintaining HIV viral suppression with ART can optimize health outcomes 
among PLWH and limit transmission to others (3, 4). Monitoring viral suppression is thus an 
important aspect of HIV care. Identifying predictors of nonsuppression and groups at 
increased risk for it can enhance intervention efforts.
Reports from individual clinics suggest high levels of viral suppression (5), but current 
large-scale estimates from across the United States are limited. One of the best assessments 
was from the North American AIDS Cohort Collaboration on Research and Design (NA-
ACCORD), which found peak viral suppression of 72%; however, key potential predictors, 
such as adherence and substance use, were not examined (6). Furthermore, this analysis only 
included data through 2008 and did not examine potential improvements in viral suppression 
due to recent changes in ART regimens, such as increased use of integrase strand transfer 
inhibitors (ISTIs). These drugs may have superior tolerability, reduced pill burden, and 
improved virologic and immune outcomes (7–15). Up-to-date evaluations are needed to 
assess improvements in HIV care, specifically viral suppression, over the past decade.
The Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) is a cohort 
collaboration that integrates data from a large and diverse population of PLWH across the 
United States (16). CNICS captures a broad range of information associated with the rapidly 
changing course of HIV disease management. Our objective was to examine changes in viral 
suppression over time and identify associated factors. We were particularly interested in the 
association of viral suppression with changing demographic and clinical characteristics, such 
as substance use patterns, medication adherence, and ISTI use.
METHODS
Data Source
CNICS is a dynamic cohort of more than 32 000 PLWH who have had 2 or more HIV 
clinical care visits at 8 sites across the United States (Appendix Figure 1, available at 
Annals.org). Each CNICS clinic is at a Centers for AIDS Research site. The CNICS data 
repository integrates comprehensive clinical data, including laboratory test results; ART and 
other medications; diagnoses; demographic data; and historical information, including prior 
ART use, collected at initial clinic visits via standardized intake processes (16). In addition, 
in recent years, sites have initiated the CNICS clinical assessment of patient-reported 
measures and outcomes, including illicit drug use, alcohol use, adherence, and depression 
(17–20). During routine clinical care visits, PLWH use touchscreen tablets equipped with 
Web-based survey software to complete the CNICS clinical assessments (17, 21). Those 
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who appear intoxicated; have cognitive impairment; or do not speak English, Spanish, or 
Amharic are not asked to complete the assessment.
Institutional review boards at each site approved CNICS protocols.
Study Participants
The overall study sample included all CNICS participants aged 18 years or older who had a 
viral load (VL) measure as part of clinical care between 1997 and 2015. We also examined 
key subgroups, including those who were receiving ART. We included a subgroup of PLWH 
receiving ART in or after 2010 to minimize the effect of changes in treatment initiation 
guidelines. Additional subgroup sensitivity analyses were done among PLWH who had 
completed the CNICS clinical assessment of patient-reported measures, such as adherence 
and illicit drug use, and among those known to be ART-naive at initiation of CNICS care.
Outcomes
The primary outcome was viral suppression versus detection, which we defined as a VL of 
no more than 400 versus greater than 400 copies/mL to exclude clinically insignificant VL 
blips (22) and account for changing thresholds of detection over time. In addition, we 
examined a secondary outcome of VL (in copies/mL) at each time point as a continuous 
variable, which we log-transformed (in base10) due to skew. We then back-transformed VL 
coefficients by raising them to a power of 10. We calculated relative VL values, which we 
defined as the ratio of VL for PLWH with and without each characteristic of interest (such as 
ISTI use).
Predictors
We examined age, race/ethnicity, sex, HIV transmission risk factors, and CD4 cell count at 
ART initiation. Self-reported adherence to ART (23, 24), illicit drug use (including and 
excluding marijuana) (25–29), and depression (30, 31) were collected as part of the CNICS 
clinical assessment (Appendix Table 1, available at Annals.org), which was integrated into 
clinical care between 2005 and 2011 at 7 CNICS sites.
Statistical Analysis
We used χ2 tests for categorical variables and t tests for continuous variables to assess 
differences in demographic and clinical characteristics among persons with and without viral 
suppression based on VL at the end of follow-up. To understand VL trends in unadjusted 
ecological analyses (1997 to 2015), we determined the percentage of VL tests showing no 
more than 400 copies/mL each year for all patients receiving care that year (overall). We 
then examined VL trends among PLWH categorized by various factors, including age, sex, 
race/ethnicity, and HIV transmission risk factor. We examined time to viral suppression for 
the majority (>50%) of VL tests by year of ART initiation. People living with HIV typically 
had multiple measures in all years since CNICS enrollment. Because we were concerned 
that those who were lost to follow-up may have been less likely to have viral suppression, 
we repeated trend analyses limiting tests to 1 random VL result per calendar year per person 
and accounting for possible differential loss to follow-up using inverse probability of 
censoring weights based on prior VL values and demographic characteristics (age, sex, and 
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race/ethnicity) to rebalance the sample on the basis of these parameters (32). To 
operationalize this approach, separate logistic models (with age, sex, and race as covariates) 
were fit to each time point to estimate the weights. This limited potential selection bias due 
to loss to follow-up that differed on the basis of characteristics of participants who were lost 
to follow-up.
Our primary analysis was a joint longitudinal and survival model that examined associations 
between demographic and clinical characteristics and having a detectable VL among persons 
receiving ART from 1997 to 2015 while accounting for loss to follow-up (33). In this model, 
we specified the longitudinal process as a mixed logistic model with detectable VL as the 
outcome. We specified the time-to-event process as loss to follow-up (due to death or 
leaving the cohort) using a Weibull distribution. This approach was selected because of 
known limitations with less complex models (34). In particular, there was concern that the 
loss-tofollow-up process was related to the detectable VL process, and so the models for 
these 2 processes needed to be estimated jointly. Using this model allowed us to account for 
potential informative dropout due to loss to follow-up that was related to both the covariates 
included in the model and the detectable VL measures.
We repeated the analyses and limited them to patients known to be ART-naive at enrollment. 
We also conducted sensitivity analyses that added adherence, illicit drug use (opiates or 
heroin, cocaine or crack, and methamphetamine or crystal methamphetamine), and 
depression among the subset who completed the CNICS clinical assessment and included 
current substance use categorized by class (opiates or heroin, cocaine or crack, 
methamphetamine or crystal methamphetamine, marijuana, and hazardous alcohol use) with 
adherence. To minimize the effect of changes in treatment initiation guidelines, we 
conducted a subgroup analysis for 2010 to 2015, during which time the guidelines changed 
little after having been expanded to include initiation of treatment independent of CD4 cell 
count. Additional sensitivity analyses were conducted that included CD4 cell count at ART 
initiation, added a quadratic term for calendar time (year of cohort entry, centered around 
2010), excluded site, and used a different VL cut point (50 copies/mL). Finally, we repeated 
the analyses using linear mixed models with VL (log10) as a continuous outcome because 
these models inherently handle unbalanced numbers and times of observations between 
patients and clustering by participant (35).
All models were adjusted for age, sex, race/ethnicity, site, ISTI use, calendar time, and years 
of follow-up. Statistical models were fit using Stata, version 14 (Stata-Corp), with the 
GSEM package used to fit the joint longitudinal and survival models.
RESULTS
We included 31 930 PLWH from 8 CNICS sites (Appendix Figure 2, available at 
Annals.org) who had at least 1 HIV VL measurement after 1 January 1997 (mean number of 
measurements per person, 17 [SD, 16]), of whom 47% were alive and receiving care at the 
end of the study period. Eighty-two percent were men, 55% were nonwhite, and the mean 
number of HIV care visits was 22. Table 1 shows demographic and clinical characteristics 
by viral suppression status based on the most recent VL measurement. Patients with viral 
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suppression were older (46 vs. 41 years [P < 0.001]) and were more likely to have a current 
CD4 count of 0.500 × 109 cells/L or greater (58% vs. 22% [P < 0.001]) than those without 
viral suppression.
Unadjusted Viral Suppression Trends
We examined viral suppression trends from 1997 to 2015 using 553 737 VL results among 
both PLWH who were using ART and those not using it. The number of PLWH with VL 
tests ranged from 3004 to 14 659 per year, and the number of tests ranged from 9193 to 39 
715 per year. Viral suppression increased from 32% in 1997 to 86% in 2015 based on all VL 
values (Figure 1). Results were similar when we limited random VL tests to 1 per person per 
year and when we corrected for loss to follow-up using inverse probability weights 
(Appendix Figure 3, available at Annals.org).
The percentages of tests showing viral suppression by demographic group are shown in 
Figure 2. The percentage of tests showing viral suppression increased by about 5% with 
each decade of age, was about 3% higher for men versus women, was about 8% lower in 
black versus white PLWH, and was about 6% lower in those whose HIV transmission risk 
factor was injection drug use compared with men who have sex with men.
We examined viral suppression after ART initiation by calendar period. For example, among 
the cohort commencing ART between 1997 and 2000, most VL tests showed suppression in 
9 months. In contrast, in the cohort initiating ART after 2010, most tests showed suppression 
in 2 months (Figure 3). Differences in testing frequency were probably not the primary 
driver of these results given that the median time to the initial test was 77 days for the cohort 
initiating ART in 1997 to 2000 versus 75 days for the cohort initiating ART after 2010.
Trends Among PLWH Receiving ART in 2010 to 2015
Among the subgroup of 20 281 PLWH receiving ART in the current treatment era (2010 to 
2015), the percentage receiving ART increased each year, from 86% in 2010 to 93% in 
2015. The percentage for whom all results in a given year were no more than 400 copies/mL 
also increased each year, from 75% in 2010 to 86% in 2015. Mean adherence did not 
increase over this period, with about 71% reporting greater than 95% adherence and about 
82% reporting greater than 90% adherence. Similarly, about 18% of PLWH reported current 
illicit drug use each year from 2010 to 2015.
Factors Associated With VL in Adjusted Analyses
In joint longitudinal and survival models of patients receiving ART from 1997 to 2015, 
black race (odds ratio [OR], 1.68 [95% CI, 1.57 to 1.80]; P < 0.001) was associated with 
increased odds of having a detectable VL in adjusted analyses (Table 2). Older age (OR, 
0.76 per decade [CI, 0.74 to 0.78]), Hispanic ethnicity (OR, 0.81 [CI, 0.74 to 0.90]), 
calendar time (OR, 0.83 [CI, 0.83 to 0.84]), years of follow-up (OR, 0.79 [CI, 0.79 to 0.80]), 
and use of ISTI-based regimens (OR, 0.54 [CI, 0.51 to 0.57]) were associated with lower 
odds of having a detectable VL (P < 0.001 for each). The shape parameter of the Weibull 
distribution was less than 1 (k = 0.59 [CI, 0.58 to 0.60]), indicating that attrition tends to 
occur early in care and PLWH are less likely to censor the longer they are in care.
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Examining VL as a continuous outcome led to similar findings, such as black race and 
younger age being associated with higher relative VL and Hispanic ethnicity and ISTI use 
being associated with lower relative VL (Table 2).
We repeated the analyses among the subgroup of patients receiving ART who were known to 
be ART-naive when joining CNICS (n = 16 019) (Appendix Table 2, available at 
Annals.org). The findings in this subpopulation were similar to the overall findings, with 
black race being associated with higher odds of a detectable VL (OR, 1.69 [CI, 1.55 to 
1.84]) and greater relative VL (1.62 [CI, 1.51 to 1.74]) in adjusted analyses. Older age and 
Hispanic ethnicity were associated with lower odds of a detectable VL (ORs, 0.83 [CI, 0.80 
to 0.86] and 0.84 [CI, 0.75 to 0.94], respectively) and lower relative VL (0.88 [CI, 0.86 to 
0.91] and 0.89 [CI, 0.81 to 0.98], respectively). Finally, ISTI use also was associated with 
lower odds of a detectable VL (OR, 0.66 [CI, 0.62 to 0.71]) and lower relative VL (0.79 [CI, 
0.76 to 0.83]).
In sensitivity analyses among the subgroup of patients receiving ART who had completed 
the CNICS clinical assessment, older age and ISTI use were consistently associated with 
lower relative VL. Higher adherence also was associated with lower relative VL (0.84 [CI, 
0.83 to 0.84]), whereas illicit drug use (1.48 [CI, 1.40 to 1.57]) and depression (1.29 [CI, 
1.23 to 1.35]) were associated with higher relative VL (Appendix Table 3, available at 
Annals.org). Similar patterns also were found in joint longitudinal and survival models with 
both adherence and category of substance use included in the same model (Appendix Table 
4, available at Annals.org). Inclusion of these covariates led to a minimal attenuation in the 
association of calendar time with viral suppression, with an OR of 0.90 (CI, 0.87 to 0.93) 
compared with 0.83 (CI, 0.83 to 0.84) in models not adjusted for these confounding factors.
Findings were similar in sensitivity analyses that were limited to PLWH receiving ART 
between 2010 and 2015 to minimize the effect of changes in ART treatment guidelines 
(Appendix Table 5, available at Annals.org). Findings were also similar in sensitivity 
analyses that also included CD4 cell count at ART initiation, with black race associated with 
higher relative VL and older age, Hispanic ethnicity, and ISTI use associated with lower 
relative VL (Appendix Table 6, available at Annals.org). In addition, higher CD4 count at 
ART initiation was associated with lower relative VL (0.83 [CI, 0.82 to 0.84] per 0.100 × 
109 cells/L). Findings were also similar in sensitivity analyses that included models that 
added a quadratic term for calendar time (Appendix Table 6), used a lower limit of VL 
quantitation, and excluded site as a covariate (data not shown).
DISCUSSION
We examined patterns of viral suppression among PLWH over time across the United States 
and showed a nearly 3-fold improvement in the rate of viral suppression, from 32% in 1997 
to 86% in 2015. In unadjusted analyses, we found that the percentage of VL tests showing 
suppression differed among key demographic groups, such as black versus white persons, 
young versus old persons, and women versus men. Overall, time from ART initiation to viral 
suppression decreased and viral suppression increased over time. In adjusted analyses of 
patients receiving ART, factors associated with viral suppression and lower relative VL 
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included demographic and clinical characteristics, such as older age and ISTI use. These 
findings persisted in analyses limited to 2010 and after (when almost everyone met criteria 
for ART initiation) and in sensitivity analyses that included substance use and ART 
adherence.
The large improvements in viral suppression at sites across the United States corroborate 
findings from prior studies that have shown increased suppression over time (6). For 
example, NA-ACCORD demonstrated a 26% increase in the percentage of PLWH who had 
viral suppression between 2000 and 2008, but this period did not capture use of newer 
regimens that are potentially more potent and tolerable.
Of note, when we focused on the current treatment era (for which published data are sparse), 
we showed increased viral suppression over time among patients receiving ART, which 
suggests that factors beyond wider ART use accounted for the improved outcomes. Although 
adherence and substance use are important factors in viral suppression rates at an individual 
level (36, 37), average adherence did not improve and substance use did not decrease over 
time between 2010 and 2015. Statistical models that were further adjusted for these 2 factors 
showed only small levels of attenuation in the association between calendar time and viral 
suppression. These results do not support the idea that population-level changes in 
adherence and substance use were driving improved suppression rates over time in the most 
recent era.
More widespread ART use, including initiation of ART, was the most important driver of 
viral suppression among PLWH. However, among those receiving ART, we found that ISTI 
use increased and was likely an important contributing factor to viral suppression. This was 
true in all sensitivity models, including those limited to patients who were known to be ART-
naive when they initiated care. Sensitivity analyses that included CD4 cell count at ART 
initiation were done to address the possibility that patients using ISTIs or initiating ART 
more recently were doing so at a higher CD4 cell count, but results were similar even after 
adjustment for baseline CD4 cell count. Several factors may contribute to improved 
suppression in PLWH using ISTIs compared with those using other ART regimens, 
including greater tolerability, enhanced potency, single-tablet regimens containing ISTIs, or 
a higher bar to the development of drug resistance during periods of less-than-perfect 
adherence.
Despite the clinically and statistically significant achievements in viral suppression, 
disparities persist. For example, we found that PLWH who were younger or black were more 
likely to have a detectable VL, whereas those who were Hispanic were less likely to have a 
detectable VL in most but not all models. These findings are consistent with a study 
demonstrating differences in HIV care cascade steps in 2009, including viral suppression by 
demographic characteristics (38). Although National HIV Surveillance System data showed 
lower overall viral suppression rates in 2014 than we observed, they also showed lower rates 
of viral suppression among black compared with white or Hispanic men who had sex with 
men (39). Other studies demonstrated that suppression rates improved during 2009 to 2013 
but still remained lower among black versus white persons (40), possibly due to differences 
in adherence (41). Whether due to differences in substance use, adherence, or other factors 
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(such as medical mistrust) (42), taken together, these findings suggest the need for culturally 
tailored interventions to encourage ART use, enhance medication adherence, and improve 
viral suppression and other outcomes.
Strengths of our study include the large number of PLWH from multiple sites across the 
United States who are engaged in care, thus providing geographic, racial/ ethnic, and clinical 
diversity. This enhances generalizability compared with trials and interval cohorts that are 
restricted to PLWH who are willing to return for scheduled visits instead of clinical care. 
CNICS contains comprehensive clinical data, including factors that are often not available, 
such as measures of adherence and substance use.
Observational data have limitations, particularly with regard to causal inference, although 
the prospective data collection and comprehensive clinical data of CNICS minimize some of 
these concerns. Temporal trends in increased ISTI use overlapped with increased viral 
suppression rates, but these rates were improving before ISTIs were introduced. However, 
models of the association of ISTI use with viral suppression were adjusted for calendar time 
and both factors were statistically significant, so both are probably independent associations. 
Our adherence measure was self-reported, and its accuracy may have varied across 
demographic groups; however, we do not expect the accuracy to have changed over time. 
Self-reported adherence may have lacked sensitivity to detect changes in adherence. In 1997, 
11% of VL tests had a lower limit of detection of less than 500 copies/mL (rather than <400 
copies/mL); therefore, values of 400 to 500 copies/mL from these tests would have been 
misclassified as viral suppression. People living with HIV may have previously received 
care elsewhere, although results of sensitivity analyses among the subset of PLWH who 
were known to be ART-naive at initiation of CNICS care were similar to the main analyses. 
Differences in the number of clinic visits and VL measures among those with viral 
suppression versus those without could be concerning; however, trend findings were the 
same in analyses using 1 random VL test per person per year rather than all VL tests. We 
used inverse probability weights to provide reassurance that loss to follow-up was likely not 
driving trends, and we also used joint longitudinal and survival models, which account for 
censoring due to loss from care. Although we used statistical techniques to account for the 
possibility of bias due to loss to follow-up, there may be residual bias due to an unmeasured 
or unknown driver of this loss to follow-up. Finally, CNICS sites may differ from lower-
resource clinical settings, and PLWH in CNICS differ from those from other data sources, 
such as the National HIV Surveillance System (39), in that CNICS includes only adult 
PLWH receiving clinical care, which may limit generalizability. Similar analyses that 
include different clinical settings could broaden understanding of viral suppression trends in 
the United States.
In conclusion, because viral suppression is essential for optimal HIV outcomes as well as 
HIV prevention efforts, understanding current trends and predictors is imperative to target 
public health policy. We must strive to decrease disparities for black PLWH and younger 
patient groups who may have poorer access to treatment. However, marked improvement in 
levels of viral suppression over time among PLWH across the United States bodes well for 
the long-term health outcomes of the current generation of PLWH and the possibility of 
limiting HIV transmission to others. Changes in ART treatment guidelines, with earlier ART 
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initiation, are clearly a major contributor to higher viral suppression rates; however, even 
among patients receiving ART in the recent treatment era, suppression rates continue to 
improve. More potent, better-tolerated regimens, including ISTIs, may play a role in this 
success.
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Appendix Figure 1. 
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Map of CNICS sites. CNICS = Centers for AIDS Research Network of Integrated Clinical 
Systems.
Appendix Figure 2. 
CNICS inclusion and exclusion criteria. Table 1 and Figures 1 and 2 include all participants 
with ≥1 VL measurement (n = 31 930) (middle box), whereas Table 2 is limited to those 
receiving ART (n = 28 520) (bottom box). ART = antiretroviral therapy; CNICS = Centers 
for AIDS Research Network of Integrated Clinical Systems; VL = viral load.
Appendix Figure 3. 
Percentage of tests showing viral suppression, with all tests included; limited to 1 random 
test per person per year; and limited to 1 random test per person per year, with correction for 
loss to follow-up with inverse probability of censoring weights based on prior viral load 
values and demographic characteristics.
Nance et al. Page 12




















HIV transmission risk factor Men who have sex with men
Injection drug use or injection drug use and men who have sex with men
Heterosexual
Other
Adherence to ART 30-day visual analogue scale (continuous variable)
Illicit drug use ASSIST instrument categorized 2 ways:
 Binary variable indicating any illicit drug use (not including marijuana)
 Categories of individual drug use: cocaine/crack, methamphetamine/crystal 
methamphetamine, opiate/heroin, or marijuana use in the past 3 months
Hazardous alcohol use AUDIT-C instrument with a score ≥5 for men and ≥4 for women to define hazardous 
use
Depression symptom severity PHQ-9, categorized as depressed or not based on a score ≥10
ART = antiretroviral therapy; ASSIST = Alcohol, Smoking and Substance Involvement Screening Test; AUDIT-C = 
Alcohol Use Disorders Identification Test–Consumption; PHQ-9 = 9-item Patient Health Questionnaire.
Appendix Table 2.
Factors Associated With Detectable VL or Amount of VL in Adjusted Models Among 
Patients Receiving ART Who Were Known to be ART-Naive at CNICS Enrollment (n = 16 
019)*
Covariate Joint Longitudinal and Survival Model† Linear Mixed Model‡
OR 95% CI P Value Relative VL 95% CI P Value
Integrase strand transfer inhibitor 
use
0.66 0.62–0.71 <0.001 0.79 0.76–0.83 <0.001
Female 1.10 1.00–1.20 0.041 1.06 0.98–1.15 0.133
Age (per decade, centered at 40 
y)
0.83 0.80–0.86 <0.001 0.88 0.86–0.91 <0.001
Race/ethnicity (reference is 
white race)
 Black 1.69 1.55–1.84 <0.001 1.62 1.51–1.74 <0.001
 Hispanic 0.84 0.75–0.94 0.002 0.89 0.81–0.98 0.020
 Other 0.76 0.65–0.89 0.001 0.85 0.75–0.96 0.012
Calendar time (year of cohort 
entry, centered around 2010)
0.88 0.87–0.89 <0.001 0.87 0.87–0.88 <0.001
Years of follow-up 0.83 0.82–0.84 <0.001 0.75 0.74–0.76 <0.001
ART = antiretroviral therapy; CNICS = Centers for AIDS Research Network of Integrated Clinical Systems; OR = odds 
ratio; VL = viral load.
*
Also adjusted for site.
†
Outcome is detectable VL (>400 copies/mL).
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Outcome is VL in log10 copies/mL.
Appendix Table 3.
Factors Associated With Amount of VL in Adjusted Models That Also Included Adherence, 
Substance Use, and Depression Among Patients Receiving ART*
Covariate Linear Mixed Models†
Relative VL 95% CI PValue Relative 
VL 
95% CI
PValue Relative VL 95% CI PValue
Integrase strand 
transfer inhibitor use
0.92 0.88–0.97 0.001 0.90 0.86–0.95 <0.001 0.91 0.87–0.96 <0.001
Female 1.05 0.96–1.15 0.29 1.17 1.06–1.28 0.002 1.11 1.01–1.22 0.039
Age (per decade, 
centered at 40 y)
0.92 0.89–0.95 <0.001 0.87 0.84–0.90 <0.001 0.86 0.84–0.89 <0.001
Race/ethnicity (reference is white race)
 Black 1.35 1.25–1.46 <0.001 1.46 1.35–1.59 <0.001 1.48 1.36–1.61 <0.001
 Hispanic 0.95 0.86–1.04 0.24 0.92 0.83–1.01 0.091 0.92 0.83–1.01 0.082
 Other 0.99 0.86–1.14 0.89 1.03 0.88–1.20 0.73 1.02 0.87–1.18 0.82
Calendar time (year of 
cohort entry, centered 
around 2010)
0.92 0.90–0.94 <0.001 0.92 0.90–0.95 <0.001 0.93 0.91–0.95 <0.001
Years of follow-up 0.89 0.88–0.90 <0.001 0.84 0.83–0.85 <0.001 0.84 0.83–0.85 <0.001
Adherence (per 10%)‡ 0.84 0.83–0.84 <0.001 - - - - - -
Current illicit drug 
use§
- - - 1.48 1.40–1.57 <0.001 - - -
Depression∥ - - - - - - 1.29 1.23–1.35 <0.001
ART = antiretroviral therapy; VL = viral load.
*
Also adjusted for site.
†
Outcome is VL in log10 copies/mL.
‡
Measured using a 30-day visual analogue scale.
§
Includes cocaine/crack, methamphetamine/crystal methamphetamine use, and heroin/opiates.
∥
Based on 9-item Patient Health Questionnaire score ≥10.
Appendix Table 4.
Factors Associated With Detectable VL in Adjusted Models That Also Included Adherence 
and Substance Use Among Patients Receiving ART*
Undetectable VL OR 95% CI P Value
Integrase strand transfer inhibitor use 0.81 0.73–0.90 <0.001
Female 1.14 0.95–1.37 0.167
Age (per decade, centered at 40 y) 0.77 0.72–0.82 <0.001
Race/ethnicity (reference is white race)
 Black 1.97 1.69–2.31 <0.001
 Hispanic 0.93 0.76–1.14 0.49
 Other 1.02 0.74–1.40 0.92
Calendar time (year of cohort entry, centered around 2010) 0.90 0.87–0.93 <0.001
Years of follow-up 0.89 0.87–0.91 <0.001
Adherence 0.97 0.97–0.97 <0.001
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Undetectable VL OR 95% CI P Value
Cocaine/crack use 1.16 0.99–1.36 0.069
Methamphetamine/crystal methamphetamine use 1.90 1.63–2.22 <0.001
Opiate/heroin use 1.25 0.96–1.61 0.093
Marijuana use 1.10 0.99–1.23 0.069
Hazardous alcohol use 0.90 0.81–1.01 0.070
ART = antiretroviral therapy; OR = odds ratio; VL = viral load.
*
Survival model component included in Appendix Table 8.
Appendix Table 5.
Factors Associated With Detectable VL in Adjusted Models Among Patients Receiving ART 
in 2010 to 2015
Covariate Joint Longitudinal Survival Model* Linear Mixed Model†
OR 95% CI P Value Relative VL 95% CI P Value
Integrase strand transfer inhibitor use 0.67 0.63–0.72 <0.001 0.78 0.76–0.81 <0.001
Female 1.23 1.11–1.36 <0.001 1.14 1.07–1.21 <0.001
Age (per decade, centered at 40 y) 0.69 0.67–0.72 <0.001 0.85 0.83–0.87 <0.001
Race/ethnicity (reference is white 
race)
 Black 2.09 1.89–2.30 <0.001 1.54 1.46–1.65 <0.001
 Hispanic 0.84 0.74–0.96 0.01 0.91 0.84–0.98 0.014
 Other 0.88 0.73–1.06 0.2 0.93 0.83–1.04 0.197
Calendar time (year of cohort entry, 
centered around 2010)
1.14 1.10–1.17 <0.001 0.98 0.96–1.00 0.016
Years of follow-up 0.79 0.78–0.81 <0.001 0.78 0.77–0.79 <0.001
ART = antiretroviral therapy; OR = odds ratio; VL = viral load.
*
Outcome is detectable VL (>400 copies/mL).
†
Outcome is VL in log10 copies/mL.
Appendix Table 6.
Factors Associated With Amount of VL in Adjusted Models That Also Included CD4 Cell 
Count at ART Initiation and Cohort Year Squared Among Patients Receiving ART*
Covariate Linear Mixed Models†
Relative VL 95% CI P Value Relative VL 95% CI P Value
Integrase strand transfer inhibitor use 0.71 0.68–0.73 <0.001 0.70 0.67–0.72 <0.001
Female 1.05 0.98–1.12 0.141 0.99 0.93–1.06 0.86
Age (per decade, centered at 40 y) 0.82 0.80–0.84 <0.001 0.83 0.81–0.85 <0.001
Race/ethnicity (reference is white 
race)
 Black 1.41 1.33–1.50 <0.001 1.60 1.51–1.70 <0.001
 Hispanic 0.77 0.71–0.83 <0.001 0.90 0.83–0.97 0.006
 Other 0.81 0.73–0.90 <0.001 0.89 0.80–0.99 0.039
Calendar time (year of cohort entry, 
centered around 2010)
0.85 0.85–0.86 <0.001 0.88 0.87–0.89 <0.001
Nance et al. Page 15













Covariate Linear Mixed Models†
Relative VL 95% CI P Value Relative VL 95% CI P Value
Years of follow-up 0.75 0.74–0.75 <0.001 0.75 0.74–0.75 <0.001
CD4 count at ART initiation (per 
0.100 × 109 cells/L)
0.83 0.82–0.84 <0.001 - - -
Cohort entry year squared (from 
2010)
- - - 1.01 1.00–1.01 <0.001
ART = antiretroviral therapy; VL = viral load.
*
Also adjusted for site.
†
Outcome is VL in log10 copies/mL.
Appendix Table 7.
Survival Model for the Joint Longitudinal and Survival Model (Using a Weibull Distribution 
With Shape Parameter k = 0.59) for Loss to Follow-up Among Patients Receiving ART
Covariate HR 95% CI P Value
Integrase strand transfer inhibitor use 0.35 0.33–0.38 <0.001
Female 0.96 0.91–1.01 0.08
Age (per decade, centered at 40 y) 0.85 0.83–0.86 <0.001
Race/ethnicity (reference is white race)
 Black 1.08 1.04–1.13 <0.001
 Hispanic 0.67 0.63–0.71 <0.001
 Other 1.06 0.97–1.15 0.192
Calendar time (year of cohort entry, centered around 2010) 1.05 1.05–1.06 <0.001
ART = antiretroviral therapy; HR = hazard ratio.
Appendix Table 8.
Survival Model for the Joint Longitudinal and Survival Model (Using a Weibull Distribution 
with Shape Parameter k = 0.59) With Adherence and Substance Use Classes Included
Time to Loss to Follow-up HR 95% CI P Value
Integrase strand transfer inhibitor use 0.58 0.52–0.64 <0.001
Female 0.90 0.80–1.02 0.113
Age (per decade, centered at 40 y) 0.87 0.83–0.90 <0.001
Race/ethnicity (reference is white race)
 Black 0.87 0.78–0.96 0.008
 Hispanic 0.69 0.62–0.78 <0.001
 Other 0.93 0.77–1.12 0.45
Calendar time (year of cohort entry, centered around 2010) 1.15 1.12–1.18 <0.001
Adherence 1.00 1.00–1.00 0.61
Cocaine/crack use 1.00 0.85–1.17 0.99
Methamphetamine/crystal methamphetamine use 1.01 0.88–1.16 0.87
Opiate/heroin use 1.10 0.85–1.42 0.46
Marijuana use 1.08 0.99–1.18 0.074
Hazardous alcohol use 1.46 1.33–1.60 <0.001
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HR = hazard ratio.
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Percentage of tests showing viral suppression over time among all patients.
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Percentage of tests showing viral suppression over time among all patients, by demographic 
and clinical characteristics. IDU = injection drug use; MSM = men who have sex with men.
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Percentage of tests showing viral suppression over time among patients receiving ART, by 
time of ART initiation. ART = antiretroviral therapy.
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